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Methods: The present study is conducted on 17,131 sam-
ples (blood donors and suspected patients reported to the
Central Blood Bank the achievement of conformation tests
in Al-Madina Al-Mounawara Saudi Arabia). Virus was
detected by two techniques: PCR and ELISA. COBAS
TagMan V2.0 was used as PCR test to measure
HBV-DNA in human plasma or serum. Three different
ELISA tests had been used to detect HBV antigen and
antibody: HBsAg, HBcAb and HBsAb.
Results: The overall prevalence of hepatitis B surface anti-
gen (HBsAg) was (9.02%), hepatitis B core antibody
(HBcAb) was (9.02%), hepatitis B surface antibody
(HBsAb) was approximately (7.93%) and hepatitis B
DNA (HBVDNA) was the highest one (9.29%).
Conclusion: Comparison of PCR positive results with those
of the ELISA positive indicates that the PCR technique is
more sensitive and reliable than the ELISA technique, as
not all ELISA positive cases confirmed HBV infection.
Keywords: Almadinah Almunawwarah; Blood donor’s;
Detection; HBV; Molecular
 2014 Taibah University. Production and hosting by Elsevier
Ltd. All rights reserved.
Introduction
Hepatitis B virus (HBV) infects the liver of humans causing an
inflammation called hepatitis. The disease was originally
known as ‘‘serum hepatitis”.1
Complications such as cirrhosis and hepatocellular carci-
noma (HCC) usually occur. It was estimated that approxi-
mately 2 billion people have serological evidence of past or
present HBV infection. More than 350 million are chronic
carriers of HBV.2
Approximately 75% of chronic carriers live in Asia and the
Western Pacific. It was reported that 15–40% of HBV infected
patients would develop cirrhosis, liver failure, or HCC, and
500,000 to 1.2 million people die of HBV infection annually.
Because of the high HBV-related morbidity and mortality,
the global disease burden of HB is substantial.3–5
The average prevalence rate of HBsAg among adults in
Saudi population is approximately 8% and 60% of them
having evidence of past exposure to (HBV). However, several
surveys of voluntary blood donors have shown marked regio-
nal variations in the prevalence of (HBV). Arya et al. (1985)
reported Jizan region of KSA as an area of hyper-endemic
(HBV) infection, with a rate of HBsAg to be 32.2% among
237 blood donors, compared to a rate of 4.7% in a similar
population in Riyadh in the Central region of KSA.6–8
The viral etiology of hepatitis B was firmly established by
electron microscopy and the detection of several viral particles
(referred to as Dane particles) that reacted with antisera to
Australia antigen. It is a partially double-stranded DNA virus
and one of many unrelated viruses that cause viral hepatitis. It
was demonstrated that the Dane particle was HBV, and its sur-
face component was designated hepatitis B surface antigen
(HBsAg). The core component contained endogenous DNA
and hepatitis core antigen (HBcAg). The differential presence
of HBsAg, antibodies to HBsAg (anti-HBs), and antibodies
to HBcAg (anti-HBc) was used to classify patients as having
acute or chronic infections.9–11
Hepatitis B viruses cause an acute illness with patients
having symptoms of acute jaundice and very high serum
ALT (a part of liver function tests). In majority (90%) of
adults, acute hepatitis B resolves within 2–3 months with full
recovery. The scenario is different in newborn up to 5 years
of age where full recovery is seen only in 10% while 90%
develop chronic liver disease. In acute hepatitis C full recovery
occurs in only 20–30% of cases while 70–80% require treat-
ment for clearance of disease as they may go onto develop
chronic liver disease.12,13
Majority of hepatitis B cases that we see are in children and
neonates who have been exposed to this virus in early life and
have carried the virus due to reasons mentioned above.14
If a person has two positive reports of HBsAg 6 months
apart, then there is almost a 100% chance that this individual
will carry the virus throughout his/her life and will always be
found positive on tests whenever tested. Natural seroconver-
sion over years occurs in 5–20% cases in each country depend-
ing upon the genes and genotypes of HBV.15
Once exposed to hepatitis B virus, antibodies develop natu-
rally in over 90% adults within 6 months of exposure. Vacci-
nation also produces antibodies in over 90%. Antibodies
(Anti HBs) once produced either following natural recovery
or following vaccination persist throughout their life, though
their levels may go down with time. Any exposure to the virus
any time after production of antibodies will automatically
enhance antibody production during that period to protect
the individual.16
Materials and Methods
The aim of this study is to diagnose the serological hepatitis B
virus picture in ELISA positive voluntary blood donors using
PCR techniques, and compare the results with those reported
on Jzan (1985).7
Seventeen thousands and one hundred thirty-one patients
suspected of HBV infected and volunteer blood donors
were identified from King Fahd Hospital in Al-Madina Al-
Mounawara and Blood Bank during 2012. A blood sample
is drawn by a needle from a vein in the arm. Blood is usually
collected in EDTA, PPT, ACD, CPD or SST tubes but not
heparin. Then, sample was centrifuged (within 1 h of collection
to separate plasma or serum from the cells) and the plasma or
serum was transferred to a screw-cap cryo tube.
There are several ways to detect (HBV). The most common
techniques are PCR and ELISA. The COBAS Ampliprep/
COBAS TagMan HBV Test, V2.0 is a nucleic acid ampli-
fication test for the quantitation of hepatitis B virus (HBV)
DNA in human plasma and serum. Test is based on two major
processes: (1) specimen preparation to isolate HBV DNA and
(2) simultaneous PCR amplification of target DNA and decep-
tion of cleaved dual-labeled oligonucleotide detection probe
specific to the target. The COBAS Ampliprep/COBAS
TagMan HBV Test, V2.0 utilizes automated specimen prep-
aration on the COBAS instrument by a Generic silica-based
capture technique. The procedure processes 500 lL of plasma
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or serum. The HBV virus particles are lysed by incubation at
elevated temperature with a protease and chaotropic lysis/
binding buffer that release nucleic acids and protects the
released HBV DNA from DNases in plasma and serum.
Protease and a known number of HBV QS DNA molecules
are introduced into each specimen along with the lysis reagent
and magnetic glass particle. Subsequently, the mixture is incu-
bated and the HBV DNA and HBV QS DNA are bound to the
surface of the glass particles. Unbound substances, such as
salts, proteins and other cellular impurities, are removed by
washing the magnetic glass particles. After separation the
beads and completion the washing steps, the adsorbed nucleic
acids are eluted at elevated temperature with an aqueous solu-
tion. The processed specimen, containing the magnetic glass
particles as well as released HBV DNA and HBV QS DNA,
is added to the amplification mixture and transferred to the
COBAS TagMan Analyzer.17
For ELISA no special preparation of the patient is required
prior to blood collection and either serum or plasma specimens
can be used with this test kit. We used three different Elisa
tests. HBsAg ELISA Kit is a fast test for the qualitative detec-
tion of the presence of HBsAg in serum or plasma. HBsAb
ELISA Kit micro titer wells of the plate are covered with the
HBsAg antigen (solid phase). Specimens of serum or plasma
containing HBsAb antibodies are added to the wells together
with an HBsAg conjugated with peroxidase. After incubation,
it will form an antigen–antibody–antigen complex represented
by the HBsAg conjugated to peroxidase, by the HBsAb anti-
body from the specimen, and by the HBsAg antigen bound
to the micro titer well. HBcAb ELISA Kit micro titer wells
are covered with recombinant antigens of the core of hepatitis
B virus (solid phase). Serum or plasma specimens containing
Anti-HBcAg antibodies (HBcAb) and anti-HBcAg (HBcAb)
– peroxidase conjugate compete to bind to the limited number
of solid phase sites (Table 1).18–21
Results
In total, 17,131 patients enrolled and among them males were
45.55% and females were 55.45% with different ages and
nationality. Most of the patients are suspected to have HBV
with different symptoms. Tests were processed upon three
different antigen–antibody reactions (HBsAg, HBcAb and
HBsAb) and virus DNA. The data obtained in this study
Figure 1: Comparison of positive results between different tests of
ELISA and PCR.
Figure 2: The relation between gender of patients and occurrence
of HBsAg, HBcAb, HbsAb or HBV-DNA due to an infection by
HBV.
Figure 3: Comparison of detection of HBsAg and HBsAb using ELISA and positive result percentage.
Figure 4: Comparison of detection of HBsAg and HBcAb using ELISA and positive result percentage.
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clearly confirm the existence of HBV in 9.29% of cases by
molecular detection (DNA), while 9.02% cases were positive
to HBV on ELISA detection (Table 2, Figures 1–4) .
Samples were collected from 1653 suspected patients, and
15,478 blood donors. All samples were tested for HBV-DNA
and presented positive for suspected patient up to 82.2%,
while only 1.51% for blood donors (Table 3, Figure 5).
Discussion
This study reflect the prevalence of hepatitis B using the
ELISA and PCR techniques for the determination HBV val-
ues, and indicate the presence of viral infection between male
and female Saudi blood donors. Meanwhile, compare the effi-
ciency of PCR technique as an alternative to ELISA technique.
Our study confirmed that the spread of HBV infection in
Al-Madina Al-Mounawara is less than that reported in Jizan
19858; That was confirmed when we conducted 17,131 sample
collected from male and female population (blood donors and
suspected patient reported to the central blood bank (the
achievement of conformation tests)) in Al-Madina Al-
Mounawara Saudi Arabia. The overall prevalence of hepatitis
B surface antigen (HBsAg) was (9.02%), hepatitis B core anti-
body (HBcAb) was (9.02%), hepatitis B surface antibody
(HBsAb) was approximately (7.93%) and hepatitis B DNA
(HBVDNA) was the highest one (9.29%). The comparison
of the PCR positive results with those of the ELISA positive,
indicates that the PCR technique is more sensitive and reliable
than the ELISA technique (Table 3).
The hepatitis B surface antigen (HBsAg) is most frequently
used to screen for the presence of this infection. It is the first
detectable viral antigen to appear during infection. However,
early in an infection, this antigen may not be present and it
may be undetectable later in the infection as it is being cleared
by the host.22 The obtained results confirm the great impor-
tance of the PCR technique in accuracy and reliability of
detection and diagnosis of hepatitis viral infection during the
cancelation of the antigen ‘‘window period” of hepatitis B
infection.
Table 1: Different types of antigen, antibody and DNA of HBV used to diagnose HBV among ELISA and PCR with different own leads for
each one.
HBsAg Surface protein contained within the lipoprotein coat
HBsAb Antibody to HBsAg, indicator of recovery/immunity to HBV infection
HBeAg Viral product secreted in blood, marker of infectivity, active replication (though absent in precore mutants)
HBeAb Antibody to HBeAg, denoting decreased infectivity
HBcAg Core antigen (viral capsid), intracellular and not detected in serum
HBcAb IgM Antibody denoting recent HBV infection or exacerbation
HBcAb IgG Contamination marker, positive after HBV contact
HBV DNA Quantitative indicator of virus in blood
Figure 5: Comparison of positive result percentage between suspected patients and volunteer blood donors.
Table 2: Summarization of the results of the whole study.
Tests HBsAg HBcAb HBsAb HBV-DNA
Positive tests 1545 (9.02%) 1545 (9.02%) 1359 (7.93%) 1592 (9.29%)
Negative tests 15,586 15,586 15,772 15,539
Rate 10:1 10:1 12:1 9:1
Positive male 704 704 619 725
Positive female 841 841 740 867
Negative male 7099 7099 7184 7078
Negative female 8487 8487 8588 8461
Total tests 17,131 17,131 17,131 17,131
Table 3: The results of the whole study of suspected patients and
blood donors by HBVDNA.
HBVDNA Whole tests count Positive tests Percentage %
Suspected 1653 1359 82.2
Blood donors 15,478 233 1.51
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Recommendations
According to our obtained result, we can strongly recommend
the use of PCR as the reliable most accurate test for detecting
(HBV) rather than used as confirmatory test to promote the
health of the community.
Conflict of interest
We have no conflict of interest to declare.
Acknowledgments
Many thanks go to our supervisor in this research Prof. Khalil
Al-Ali – Professor of virology in Taibah University, Mr. Waeal
Alnozha – the Supervisor of Molecular Biology Lab. on Blood
Bank in Al-Madena Al-Monawara – Prof. Atef Diab, Profes-
sor of Molecular Microbiology in Taibah University and Prof.
Mohammad Abdel Razik, Professor of Medical (Mycology
and Microbiology) in Taibah University for building our inter-
est about this study and gave us all help to make it successful.
References
1. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccina-
tion and the risk of multiple sclerosis. N Engl J Med 2001; 344:
327–332.
2. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ,
et al. Clinical outcome and virologic profiles of severe hepatitis B
exacerbation due to YMDD mutations. J Hepatol 2003; 39:
850–855.
3. Gust ID. Epidemiology of hepatitis B infection in the Western
Pacific and South East Asia. Gut. 1996; 38(Suppl 2): S18–S23.
4. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682–1683;
Li JWTX, Zhong WW, Xin LZ, Jin, Fu HC. Mechanisms of
inactivation of hepatitis A virus in water by chlorine dioxide.
Water Res 2004; 38: 1514–1519.
5. Mahoney FJ. Update on diagnosis, management, and prevention
of hepatitis B virus infection. Clin Microbiol Rev 1999; 12:
351–366.
6. Parande CM, Arya SC, Ashraf SJ. Hepatitis B virus among Saudi
children in Jizan, Saudi Arabia. Infection 1986; 14: 233–235.
7. Arya SC, Ashraf SJ, Parande CM, et al. Hepatitis B virus in Jizan,
Saudi Arabia. J Med Virol 1985; 17: 267–274.
8. Al-Faleh FZ. Changing pattern of Hepatitis viral infection in
Saudi Arabia in the last two decades. Ann Saudi Med 2003; 23:
364–371.
9. MacCallum FO, Bauer DJ. Homologous serum hepatitis. Lancet
1947; ii: 691–692.
10. Dane DS, Cameron CH, Briggs. Virus-like particles in serum of
patients with Australia-antigen-associated hepatitis. Lancet 1970;
i: 695–698.
11. Magnius LO, Espmark JA. New specificities in Australia antigen-
positive sera distinct from the Le Bouvier determinants. J Immunol
1972; 109: 1017–1021.
12. Villeneuve JP. The natural history of chronic hepatitis B virus
infection. J ClinVirol 2005; 34(Suppl 1): S139–S142.
13. Central of disease control and prevention. The ABCs of Hepatitis
2012; 21-1076.
14. Hepatitis B guidelines for pregnant women. Hepatitis B Founda-
tion 2012; 215-489-4900.
15. Yuen MF, Wong DK, Zheng BJ, Chan CC, Yuen JC, Wong BC,
Lai CL. ‘‘Difference in T helper responses during hepatitis flares in
hepatitis B (e) antigen (HBeAg)-positive patients with genotypes B
and C” implication for early HBeAg seroconversion. J Viral Hepat
2007; 14: 269–275.
16. H.B.V. Infected Health Care Workers July 12. Recommendations
for preventing transmission of human immunodeficiency virus and
hepatitis b virus to patients during exposure-prone invasive
procedures. MMWR 1991; 40(RR08): 1–9.
17. The COBAS Ampliprep/COBAS TagMan. HBV Test V2.0
Manual book, Roche Molecular Systems, Inc.; 2011. Doc Rev. 7.0.
18. National Center for Biotechnology Information; March 2006. At:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1079522.
19. Bi-x-act of Finland, HBsAg ELISA 96 & 480 well blat kit (TMB).
At: http://www.ekoweb.fi/images/pdf/HbsAg_ELISA_96_well_
plate.pdf.
20. HBsAb ELISA Kit creative-diagnostics. At: http://www.creative-
diagnostics.com/description_4020_148.htm.
21. Anti-HBcAg ELISA Kit creative-diagnostics. At: http://www.
creative-diagnostics.com/description_4003_148.htm.
22. Ganem D, Prince AM. Hepatitis B virus infection—natural
history and clinical consequences. N Engl J Med 2004; 350:
1118–1129.
170 Hepatitis B virus in voluntary ELISA positive blood donors
